Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
303 questions in 64 reviews · Hepato-Biliary
current versionsNo studies 303 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Antibiotics vs placebo or no intervention Serious adverse event ‐ not reported · people with leptospirosis Antibiotics for treatment of leptospirosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prostaglandin vs placebo or standard care Health‐related quality of life · adult liver transplanted recipients Prostaglandins for adult liver transplanted recipients (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outcomes  · adults with compensated or decompensated advanced chronic liver disease Granulocyte colony‐stimulating factor with or without stem or progenitor cell or growth factors infusion for… (2023) · Cochrane | no estimate extracted | NR | No studies |
Normothermic machine perfusion (NMP) vs static cold storage (SCS) Quality of life ‐ not measured · liver transplant recipients Machine perfusion in liver transplantation (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypothermic oxygenated perfusion (HOPE) vs static cold storage (SCS) Quality of life ‐ not measured · liver transplant recipients Machine perfusion in liver transplantation (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Intraperitoneal local anaesthetic vs control Health related quality of life ‐ not measured · patients undergoing laparoscopic cholecystectomy Intraperitoneal local anaesthetic instillation versus no intraperitoneal local anaesthetic instillation for… (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Electrocoagulation in combination with allopurinol or with dimethyl sulphoxide vs control (vehicle solution of allopurinol by mouth) Tumour response · people with liver metastases Electrocoagulation for liver metastases (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Electrocoagulation alone vs control (vehicle solution of allopurinol by mouth) Other adverse events and complications · people with liver metastases Electrocoagulation for liver metastases (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Electrocoagulation alone vs control (vehicle solution of allopurinol by mouth) Failure to clear liver metastases or recurrence of liver metastases · people with liver metastases Electrocoagulation for liver metastases (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Electrocoagulation alone vs control (vehicle solution of allopurinol by mouth) Tumour response · people with liver metastases Electrocoagulation for liver metastases (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Electrocoagulation in combination with allopurinol or with dimethyl sulphoxide vs control (vehicle solution of allopurinol by mouth) Other adverse events and complications · people with liver metastases Electrocoagulation for liver metastases (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ Electrocoagulation in combination with allopurinol or with dimethyl sulphoxide vs control (vehicle solution of allopurinol by mouth) Failure to clear liver metastases or recurrence of liver metastases · people with liver metastases Electrocoagulation for liver metastases (2021) · Cochrane | no estimate extracted | NR | No studies |
Band ligation vs sham or no intervention Health‐related quality of life · children with portal hypertension and large oesophageal varices, without previous gastrointestinal bleeding or… Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in… (2021) · Cochrane | no estimate extracted | NR | No studies |
Band ligation vs sham or no intervention Adverse events considered not serious · children with portal hypertension and large oesophageal varices, without previous gastrointestinal bleeding or… Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in… (2021) · Cochrane | no estimate extracted | NR | No studies |
Adjuvant chemotherapy vs no chemotherapy Health‐related quality of life · people with resectable cholangiocarcinoma Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma (2021) · Cochrane | no estimate extracted | NR | No studies |
Adjuvant chemotherapy vs no chemotherapy Cancer‐related mortality · people with resectable cholangiocarcinoma Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma (2021) · Cochrane | no estimate extracted | NR | No studies |
Adjuvant chemotherapy vs no chemotherapy TIme to recurrence of the tumour · people with resectable cholangiocarcinoma Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma (2021) · Cochrane | no estimate extracted | NR | No studies |
Adjuvant chemotherapy vs no chemotherapy Non‐serious adverse events · people with resectable cholangiocarcinoma Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Interventions · people with liver cirrhosis and oesophageal varices with no history of bleeding Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network… (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Beta‐blockers · people with liver cirrhosis and oesophageal varices with no history of bleeding Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network… (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Interventions · people with liver cirrhosis and previous oesophageal variceal bleeding Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to… (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Sclerotherapy · people with liver cirrhosis and previous oesophageal variceal bleeding Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to… (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Interventions · people with nonalcohol‐related fatty liver disease (NAFLD) Lifestyle modifications for nonalcohol‐related fatty liver disease: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR No active intervention · people with nonalcohol‐related fatty liver disease (NAFLD) Lifestyle modifications for nonalcohol‐related fatty liver disease: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Interventions · people with non‐alcohol‐related fatty liver disease (NAFLD) Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR No active intervention · people with non‐alcohol‐related fatty liver disease (NAFLD) Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Distal splenorenal shunt vs endoscopic intervention Health‐related quality of life · participants with cirrhosis and with previous oesophagogastric variceal bleeding Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of… (2020) · Cochrane | no estimate extracted | NR | No studies |
Transjugular intrahepatic portosystemic shunt vs endoscopic intervention with or without medical treatment Health‐related quality of life · participants with cirrhosis with previous oesophagogastric variceal bleeding Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of… (2020) · Cochrane | no estimate extracted | NR | No studies |
Portosystemic shunts vs endoscopic intervention with or without medical treatment Health‐related quality of life · participants with cirrhosis and with previous oesophagogastric variceal bleeding Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of… (2020) · Cochrane | no estimate extracted | NR | No studies |
Total shunt vs endoscopic intervention Health‐related quality of life · participants with cirrhosis and with previous oesophagogastric variceal bleeding Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of… (2020) · Cochrane | no estimate extracted | NR | No studies |
Percutaneous ethanol injection vs no intervention, other ablation methods, or systemic treatment Time to mortality · patients with liver metastases Percutaneous ethanol injection for liver metastases (2020) · Cochrane | no estimate extracted | NR | No studies |
Percutaneous ethanol injection vs no intervention, other ablation methods, or systemic treatment Health‐related quality of life · patients with liver metastases Percutaneous ethanol injection for liver metastases (2020) · Cochrane | no estimate extracted | NR | No studies |
Percutaneous ethanol injection vs no intervention, other ablation methods, or systemic treatment Time to progression of liver metastases · patients with liver metastases Percutaneous ethanol injection for liver metastases (2020) · Cochrane | no estimate extracted | NR | No studies |
Percutaneous ethanol injection vs no intervention, other ablation methods, or systemic treatment Serious adverse events and complications · patients with liver metastases Percutaneous ethanol injection for liver metastases (2020) · Cochrane | no estimate extracted | NR | No studies |
Transarterial embolisation vs no intervention Time to progression of liver metastases · people with liver metastases Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases (2020) · Cochrane | no estimate extracted | NR | No studies |
Transarterial embolisation vs no intervention Tumour response measures · people with liver metastases Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases (2020) · Cochrane | no estimate extracted | NR | No studies |
Transarterial embolisation vs no intervention Health‐related quality of life · people with liver metastases Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases (2020) · Cochrane | no estimate extracted | NR | No studies |
Transarterial chemoembolisation vs no intervention Time to progression of liver metastases · people with liver metastases Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases (2020) · Cochrane | no estimate extracted | NR | No studies |
Transarterial chemoembolisation vs no intervention Tumour response measures · people with liver metastases Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases (2020) · Cochrane | no estimate extracted | NR | No studies |
Transarterial chemoembolisation vs no intervention Health‐related quality of life · people with liver metastases Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases (2020) · Cochrane | no estimate extracted | NR | No studies |
Transarterial embolisation and transarterial chemoembolisation vs no intervention Time to progression of liver metastases · people with liver metastases Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases (2020) · Cochrane | no estimate extracted | NR | No studies |
Transarterial embolisation and transarterial chemoembolisation vs no intervention Tumour response measures · people with liver metastases Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases (2020) · Cochrane | no estimate extracted | NR | No studies |
Transarterial embolisation and transarterial chemoembolisation vs no intervention Health‐related quality of life · people with liver metastases Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases (2020) · Cochrane | no estimate extracted | NR | No studies |
Radioembolisation plus sorafenib vs sorafenib monotherapy All‐cause mortality at 1 year · people with hepatocellular carcinoma Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Radioembolisation vs sorafenib Cancer‐related mortality · people with hepatocellular carcinoma Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Radioembolisation vs chemoembolisation All‐cause mortality at 1 year · people with hepatocellular carcinoma Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Radioembolisation vs chemoembolisation Cancer‐related mortality · people with hepatocellular carcinoma Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Radioembolisation plus sorafenib vs sorafenib monotherapy Health‐related quality of life · people with hepatocellular carcinoma Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Radioembolisation plus sorafenib vs sorafenib monotherapy Cancer‐related mortality · people with hepatocellular carcinoma Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Radioembolisation plus sorafenib vs sorafenib monotherapy Time to progression of the tumour (median time to progression) · people with hepatocellular carcinoma Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |